TY - JOUR
T1 - PKC- and ERK-dependent activation of IκB kinase by lipopolysaccharide in macrophages
T2 - Enhancement by P2Y receptor-mediated CaMK activation
AU - Chen, Bing-Chang
AU - Lin, W. W.
PY - 2001
Y1 - 2001
N2 - 1. Although accumulating studies have identified IκB kinase (IKK) to be essential for controlling NF-κB activity in response to several cytokines, the upstream kinases that control IKK activity are still not completely known. We have previously reported that G protein-coupled P2Y 6 receptor activation by UTP potentiates lipopolysaccharide (LPS)-induced IκB phosphorylation and degradation, and NF-κB activation in J774 macrophages. In this study, we investigated the upstream kinases for IKK activation by UTP and LPS. 2. In murine J774 macrophages, LPS-induced NF-κB activation was inhibited by the presence of PDTC, D609, Ro 31-8220, PD 098059 and SB 203580. 3. Accompanying NF-κB activation, LPS induced IκB degradation and IKK activation were reduced by PDTC, D609, Ro 31-8220 and PD 098059, but not by SB 203580. 4. Although UTP itself slightly induced IKK activation, this response was synergistic with LPS. BAPTA/AM and KN-93 (a calcium/calmodulin-dependent protein kinase (CaMK) inhibitor) attenuated UTP- but not LPS-stimulated IKK activity. Synergistic IKK activation between LPS and thapsigargin was further demonstrated in peritoneal macrophages. 5. LPS and UTP co-stimulation additively increased p65 NF-κB phosphorylation. In vitro kinase assays revealed that LPS and UTP induced extracellular signal-regulated protein kinase (ERK) and p38 mitogen-activated protein kinase activation were respectively inhibited by PD098059 and SB 203580. 6. Taken together, we demonstration that Gq protein-coupled P2Y 6 receptor activation can potentiate LPS-stimulated IKK activity. While PKC and ERK participate in IKK activation by LPS and UTP, the phosphatidylinositide-phospholipase C-dependent activation of CaMK plays a major role in UTP potentiation of the LPS response.
AB - 1. Although accumulating studies have identified IκB kinase (IKK) to be essential for controlling NF-κB activity in response to several cytokines, the upstream kinases that control IKK activity are still not completely known. We have previously reported that G protein-coupled P2Y 6 receptor activation by UTP potentiates lipopolysaccharide (LPS)-induced IκB phosphorylation and degradation, and NF-κB activation in J774 macrophages. In this study, we investigated the upstream kinases for IKK activation by UTP and LPS. 2. In murine J774 macrophages, LPS-induced NF-κB activation was inhibited by the presence of PDTC, D609, Ro 31-8220, PD 098059 and SB 203580. 3. Accompanying NF-κB activation, LPS induced IκB degradation and IKK activation were reduced by PDTC, D609, Ro 31-8220 and PD 098059, but not by SB 203580. 4. Although UTP itself slightly induced IKK activation, this response was synergistic with LPS. BAPTA/AM and KN-93 (a calcium/calmodulin-dependent protein kinase (CaMK) inhibitor) attenuated UTP- but not LPS-stimulated IKK activity. Synergistic IKK activation between LPS and thapsigargin was further demonstrated in peritoneal macrophages. 5. LPS and UTP co-stimulation additively increased p65 NF-κB phosphorylation. In vitro kinase assays revealed that LPS and UTP induced extracellular signal-regulated protein kinase (ERK) and p38 mitogen-activated protein kinase activation were respectively inhibited by PD098059 and SB 203580. 6. Taken together, we demonstration that Gq protein-coupled P2Y 6 receptor activation can potentiate LPS-stimulated IKK activity. While PKC and ERK participate in IKK activation by LPS and UTP, the phosphatidylinositide-phospholipase C-dependent activation of CaMK plays a major role in UTP potentiation of the LPS response.
KW - CaMK
KW - ERK
KW - IKK
KW - Macrophages
KW - NF-κB
KW - P2Y receptor
KW - p38 MAPK
KW - PKC
UR - http://www.scopus.com/inward/record.url?scp=0035163868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035163868&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0704334
DO - 10.1038/sj.bjp.0704334
M3 - Article
C2 - 11682454
AN - SCOPUS:0035163868
SN - 0007-1188
VL - 134
SP - 1055
EP - 1065
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 5
ER -